Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f ...

Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...

FOIA requests to the federal government often are signals. They can be an important early warning of bad publicity, litigation to come, or uncertainties to be hedged and gamed out. When the flow of ...

El Lilly’s (LLY) blockbuster weight-loss drug Zepbound is now eligible for Medicare coverage. The news could significantly ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

Recent market research reveals that glucagon-like peptide-1 (GLP-1) injections are set to dominate the obesity treatment ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that BioAge Labs, Inc. (NASDAQ: ...

Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...